Literature DB >> 12558800

A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway.

Naoki Kimura1, Chiharu Tokunaga, Sushila Dalal, Christine Richardson, Ken-ichi Yoshino, Kenta Hara, Bruce E Kemp, Lee A Witters, Osamu Mimura, Kazuyoshi Yonezawa.   

Abstract

BACKGROUND: The mammalian target of rapamycin (mTOR) regulates multiple cellular functions including translation in response to nutrients, especially amino acids. AMP-activated protein kinase (AMPK) modulates metabolism in response to energy demand by responding to changes in AMP.
RESULTS: The treatment of SV40-immortalized human corneal epithelial cells (HCE-T cells) with 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), widely used as an AMPK activator, inhibits p70 S6k activities. Altered glucose availability, which regulates AMPK activity, also modulates the activity of p70 S6k. AICAR treatment also inhibits phosphorylation of Thr-412 in the p70 S6 kinase (p70 S6k), which is indispensable for the activity. Furthermore, over-expression of mutant AMPK subunits by stable expression in rabbit pulmonary fibroblast cell lines (PS120 cells) also modulates p70 S6k activity. The insensitivity of the rapamycin-resistant p70 S6k variant to AICAR treatment suggests that the inhibition of p70 S6k is mediated through a common effector, supporting a model whereby mTOR and its downstream effector are controlled by AMPK.
CONCLUSION: These results indicate that the AMPK and mTOR signalling pathways are possibly linked. In addition to the mTOR signal acting as a priming switch that modulates p70 S6k activation, AMPK appears to provide an overriding switch linking p70 S6k regulation to cellular energy metabolism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12558800     DOI: 10.1046/j.1365-2443.2003.00615.x

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  126 in total

Review 1.  Progeria syndromes and ageing: what is the connection?

Authors:  Christopher R Burtner; Brian K Kennedy
Journal:  Nat Rev Mol Cell Biol       Date:  2010-08       Impact factor: 94.444

2.  Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signaling.

Authors:  Chongben Zhang; Angela A Wendel; Matthew R Keogh; Thurl E Harris; Jie Chen; Rosalind A Coleman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

Review 3.  The role of mammalian target of rapamycin (mTOR) in the regulation of pancreatic β-cell mass: implications in the development of type-2 diabetes.

Authors:  Jianling Xie; Terence P Herbert
Journal:  Cell Mol Life Sci       Date:  2011-11-09       Impact factor: 9.261

Review 4.  Signaling by target of rapamycin proteins in cell growth control.

Authors:  Ken Inoki; Hongjiao Ouyang; Yong Li; Kun-Liang Guan
Journal:  Microbiol Mol Biol Rev       Date:  2005-03       Impact factor: 11.056

5.  The Snf1 protein kinase and Sit4 protein phosphatase have opposing functions in regulating TATA-binding protein association with the Saccharomyces cerevisiae INO1 promoter.

Authors:  Margaret K Shirra; Sarah E Rogers; Diane E Alexander; Karen M Arndt
Journal:  Genetics       Date:  2005-02-16       Impact factor: 4.562

6.  Potentiation of insulin-stimulated glucose transport by the AMP-activated protein kinase.

Authors:  Jeong-Sun Ju; Michael A Gitcho; Carter A Casmaer; Pankaj B Patil; Dae-Gyue Han; Susan A Spencer; Jonathan S Fisher
Journal:  Am J Physiol Cell Physiol       Date:  2006-07-26       Impact factor: 4.249

Review 7.  Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.

Authors:  Sharon S McDaniel; Michael Wong
Journal:  Neurosci Lett       Date:  2011-02-24       Impact factor: 3.046

8.  Mammalian target of rapamycin complex 1 (mTORC1) plays a role in Pasteurella multocida toxin (PMT)-induced protein synthesis and proliferation in Swiss 3T3 cells.

Authors:  Hammou Oubrahim; Allison Wong; Brenda A Wilson; P Boon Chock
Journal:  J Biol Chem       Date:  2012-12-07       Impact factor: 5.157

9.  Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines.

Authors:  Medhi Wangpaichitr; Niramol Savaraj; Johnathan Maher; Metin Kurtoglu; Theodore J Lampidis
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

10.  PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.

Authors:  A Belfiore; M Genua; R Malaguarnera
Journal:  PPAR Res       Date:  2009-07-07       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.